# Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

> **NCT04643327** · PHASE2 · RECRUITING · sponsor: **The University of Queensland** · enrollment: 28 (estimated)

## Conditions studied

- Parkinson Disease
- Mild Cognitive Impairment
- Memory Impairment

## Interventions

- **DRUG:** Levetiracetam
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04643327
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-09
- **Primary completion:** 2025-01
- **Final completion:** 2025-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643327, "Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04643327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*